{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:25:21Z","timestamp":1765545921022},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/01.jaa.0000453239.92473.41","type":"journal-article","created":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T10:21:09Z","timestamp":1408789269000},"page":"37-46","source":"Crossref","is-referenced-by-count":2,"title":["Managing hypertension in patients with chronic kidney disease"],"prefix":"10.1097","volume":"27","author":[{"given":"Kim","family":"Zuber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Gilmartin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"9","key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1681\/ASN.2012040392","article-title":"Medical costs of CKD in the Medicare population.","volume":"24","author":"Honeycutt","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/j.ajkd.2013.03.009","article-title":"Lifetime incidence of CKD stages 3-5 in the United States.","volume":"62","author":"Grams","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"R6-8-20210130","first-page":"1","article-title":"Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Kidney","year":"2013","journal-title":"Kidney Int"},{"key":"R7-8-20210130","first-page":"337","article-title":"Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease.","volume":"2","author":"Kidney","year":"2012","journal-title":"Kidney Int"},{"issue":"7","key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1681\/ASN.2010030236","article-title":"Blood pressure control in chronic kidney disease: is less really more.","volume":"21","author":"Lewis","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","article-title":"Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous.","volume":"144","author":"Messerli","year":"2006","journal-title":"Ann Intern Med"},{"issue":"3","key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1681\/ASN.2006080858","article-title":"Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease.","volume":"18","author":"Weiner","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/ndt\/gfk057","article-title":"Association of low blood pressure with increased mortality in patients with moderate to severe chronic kidney disease.","volume":"21","author":"Kovesdy","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/0003-4819-159-4-201308200-00004","article-title":"Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study.","volume":"159","author":"Kovesdy","year":"2013","journal-title":"Ann Intern Med"},{"issue":"11","key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1503\/cmaj.121468","article-title":"Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis.","volume":"185","author":"Lv","year":"2013","journal-title":"CMAJ"},{"issue":"5","key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","article-title":"Management of high blood pressure in blacks: an update of the International Society on Hypertension in Blacks consensus statement.","volume":"56","author":"Flack","year":"2010","journal-title":"Hypertension"},{"issue":"4","key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7326\/0003-4819-159-4-201308200-00014","article-title":"How low can you go Blood pressure and mortality in chronic kidney disease.","volume":"159","author":"Rifkin","year":"2013","journal-title":"Ann Intern Med"},{"issue":"12","key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"d4366","DOI":"10.1136\/bmj.d4366","article-title":"Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.","volume":"343","author":"Slagman","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern.","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"10","key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1742-1241.2010.02448.x","article-title":"Is renoprotection with RAAS blockade a failed paradigm Have we learnt any lessons so far.","volume":"64","author":"Onuigbo","year":"2010","journal-title":"Int J Clin Pract"},{"issue":"18","key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/hr.2009.44","article-title":"Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.","volume":"32","author":"Saruta","year":"2009","journal-title":"Hypertens Res"},{"issue":"6","key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/ndt\/gfr696","article-title":"Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.","volume":"27","author":"Evans","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/phar.1232","article-title":"To RAS or not to RAS The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.","volume":"33","author":"St Peter","year":"2013","journal-title":"Pharmacotherapy"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/ndt\/gfq565","article-title":"Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial.","volume":"26","author":"Zamboli","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"20","key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","article-title":"ACCFAHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.","volume":"57","author":"Aronow","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"9721","key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.JAA.0000435257.26357.a8","article-title":"Medication dosing in patients with chronic kidney disease.","volume":"26","author":"Zuber","year":"2013","journal-title":"JAAPA"},{"issue":"2","key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00041552-200303000-00001","article-title":"Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations.","volume":"12","author":"Sica","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"5","key":"R33-8-20210130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11906-006-0087-7","article-title":"Lessons from the African-American study of kidney disease and hypertension: an update.","volume":"8","author":"Toto","year":"2006","journal-title":"Curr Hypertens Rep"},{"issue":"21","key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"7","key":"R37-8-20210130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2165\/00003088-200241070-00004","article-title":"Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines.","volume":"41","author":"Frishman","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"R38-8-20210130","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysis.","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"R39-8-20210130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1524-6175.2007.07161.x","article-title":"Centrally acting antihypertensive agents: an update.","volume":"9","author":"Sica","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"R41-8-20210130","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2215\/CJN.00550113","article-title":"Prevalence of apparent treatment-resistant hypertension among individuals with CKD.","volume":"8","author":"Tanner","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"R42-8-20210130","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1159\/000337571","article-title":"Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease.","volume":"120","author":"Sarafidis","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"9756","key":"R45-8-20210130","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"R46-8-20210130","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1161\/CIRCULATIONAHA.112.130880","article-title":"Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.","volume":"126","author":"Esler","year":"2012","journal-title":"Circulation"},{"issue":"15","key":"R47-8-20210130","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","article-title":"A controlled trial of renal denervation for resistant hypertension.","volume":"370","author":"Bhatt","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"R48-8-20210130","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1097\/00005344-200606001-00009","article-title":"Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage.","volume":"47","author":"Ochodnicky","year":"2006","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["Journal of the American Academy of Physician Assistants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000453239.92473.41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T18:42:20Z","timestamp":1620931340000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01720610-201409000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000453239.92473.41","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}